Benitec Biopharma (BNTC) Cash & Current Investments (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Cash & Current Investments data on file, last reported at $188.9 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Current Investments rose 141.11% year-over-year to $188.9 million; the trailing twelve-month figure through Dec 2025 stood at $188.9 million (up 141.11% YoY), and the FY2025 full-year result was $97.9 million, up 92.14% from the prior year.
• Cash & Current Investments improved to $188.9 million in Q4 2025, from $94.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $188.9 million in Q4 2025 to a low of $13000.0 in Q1 2024.
• A 5-year average of $41.9 million and a median of $18.1 million in 2021 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments slumped 99.8% in 2024 and jumped 796692.31% in 2025, its largest moves.
• Tracing BNTC's Cash & Current Investments over 5 years: stood at $12.3 million in 2021, then fell by 14.42% to $10.6 million in 2022, then soared by 93.23% to $20.4 million in 2023, then surged by 284.27% to $78.3 million in 2024, then jumped by 141.11% to $188.9 million in 2025.
• Business Quant data shows BNTC's Cash & Current Investments at $188.9 million in Q4 2025, $94.6 million in Q3 2025, and $97.9 million in Q2 2025.